Core Viewpoint - The 11th batch of national organized drug centralized procurement results has been announced, with implementation set for February 2026, focusing on maintaining clinical stability, ensuring quality, and preventing excessive competition [3][10]. Summary by Sections Procurement Results - A total of 55 drugs were included in the 11th batch of procurement, covering various therapeutic areas such as anti-infection, anti-allergy, anti-tumor, and more [3][4]. - Approximately 46,000 medical institutions participated, with 445 companies submitting bids for 794 products, resulting in 272 companies winning bids for 453 products [3][5]. Market Dynamics - The overall selection rate increased from 49% in the 10th batch to 57% in the 11th batch, attributed to the introduction of a revival mechanism allowing about 25% of companies to regain eligibility [6][10]. - The average price difference for selected drugs narrowed to 1.7 times, with 13 products triggering a price correction mechanism to maintain orderly pricing [6][7]. Competitive Landscape - The average number of companies competing per product doubled to 14 compared to 7.5 in previous batches, indicating heightened competition while maintaining a high selection rate [6][7]. - Major domestic companies like Qilu Pharmaceutical and international firms like Germany's B. Braun secured multiple selections, reflecting a balanced competitive environment [7][12]. Regulatory Improvements - The procurement rules have been continuously optimized, focusing on fairness and transparency, with new mechanisms such as anchor pricing and revival processes introduced [10][11]. - Quality control measures have been strengthened, requiring bidders to have relevant production experience and compliance with Good Manufacturing Practices (GMP) [11][12]. Industry Transformation - The centralized procurement system is pushing companies to adapt, with some focusing on compliant generic drugs while others accelerate innovation in drug development [12][14]. - The market is witnessing a shift towards high-quality, innovative products, with a significant increase in the number of approved innovative drugs and medical devices [14][15]. Future Outlook - The drug procurement system is evolving towards a more transparent and quality-focused approach, with ongoing adjustments based on feedback and practical conditions [15]. - The core principles of the procurement system remain stable, ensuring a balance between public welfare, corporate development, and high-quality industry transformation [15].

21世纪经济报道记者 闫硕 日前，第11批国家组织药品集中带量采购（简称"集采"）结果正式公布，将于2026年2月实施。 据了解，此次集采共纳入55种药品，覆盖抗感染、抗过敏、抗肿瘤、降血糖、降血压、降血脂、消炎镇 痛等领域常用药品，全部采购成功。全国共4.6万家医药机构参加报量，445家企业的794个产品参与投 标，其中272家企业的453个产品中选。 第11批集采总体实现了"稳临床、保质量、反内卷、防围标"预期目标。比如，复活环节的设置，进一步 提高了厂牌与临床实际需求的匹配度，也有利于引导企业科学研判、理性报价。 在业内专家看来，新增未入围复活机制及锚点价后，企业报价整体趋稳，既为维护市场竞争秩序提供有 力支撑，也彰显了医保部门在平衡药品降价与履约保障方面的积极探索。总体来看，本次集采更注重可 持续性与执行效能平衡，彰显政策正从"降价导向"向"质量导向"稳步转型。 截至目前，国家医保局共开展11批国家组织药品集采，成功采购490种药品，集采惠民覆盖面持续扩 大。"十五五"规划建议明确部署"优化药品集采"，国家医保局后续将加强评估、总结经验、补齐短板， 持续推动集采工作规范化、制度化、常态化开展。 以竞争 ...

Core Viewpoint - The 11th batch of national drug centralized procurement has concluded, with 55 drugs selected, aiming to provide high-quality and affordable medications to patients by February 2026. The procurement process has shown a significant shift in pricing strategies among participating companies, reflecting their operational strategies and cost control capabilities [3][5][18]. Group 1: Procurement Results - A total of 445 companies participated in the bidding, with 272 companies and 453 products winning the proposed selection, marking a historical high in participation [5][14]. - The average price difference of selected products has significantly narrowed compared to previous batches, indicating a more competitive environment [5][18]. - The introduction of measures such as a "price anchor" to prevent extreme low pricing and the revival mechanism for non-selected bids has contributed to maintaining a relatively high selection rate [5][11]. Group 2: Pricing Strategies - Companies have begun to adopt differentiated pricing strategies, moving away from irrational low bidding to more rational pricing based on their own cost structures and market assessments [5][6]. - Smaller companies are focusing on cost-effective pricing, while larger firms are either significantly lowering prices or reallocating resources towards innovative products instead of competing in the generic drug market [6][12]. Group 3: Revival Mechanism - The revival mechanism allows companies that did not initially qualify to participate in the selection process if they agree to match the prices of selected competitors, encouraging more companies to supply at reasonable prices [11][12]. - This mechanism is seen as beneficial for larger market share companies, allowing them to participate without being forced into aggressive price competition [11][12]. Group 4: Clinical Implications - The ability to report quantities by brand rather than just by generic name has clinical significance, ensuring better stability and continuity in patient medication [14][17]. - The procurement process aims to meet clinical demand while also addressing the financial burden on patients, particularly for high-cost medications like Nintedanib, which is expected to see significant price reductions [17][18].

Core Insights - The 11th round of national drug procurement has concluded, with 55 drugs selected for inclusion, aiming to provide high-quality and affordable medications to patients by February 2026 [1][4] - The procurement process has seen a significant increase in competition, with 445 companies participating and a record number of products and companies selected, indicating a shift in pricing strategies among pharmaceutical companies [4][11] Group 1: Procurement Details - A total of 445 companies submitted bids for 794 products, with 272 companies and 453 products achieving proposed selection status [4] - The average price difference for selected products has notably decreased compared to previous rounds, reflecting the effectiveness of new procurement rules [4] - The introduction of a "revival mechanism" allows companies that did not initially qualify to be reconsidered if they agree to match the prices of selected competitors [8][9] Group 2: Pricing Strategies - Companies are now adopting differentiated pricing strategies based on their operational costs and market positioning, moving away from the previous trend of irrationally low bids [4][5] - Smaller companies are focusing on cost-effective pricing, while larger firms are either significantly lowering prices or opting to invest in innovation rather than competing in the generic market [5][12] - The revival mechanism has encouraged companies to participate more actively, allowing them to choose pricing strategies that align with their business models [8][9] Group 3: Clinical Impact - The procurement aims to stabilize clinical drug supply and ensure quality, with 77% of procurement requests being brand-specific, enhancing the reliability of medication for patients [11] - The inclusion of drugs like Nintedanib is expected to significantly reduce patient costs, particularly for those with interstitial lung disease, thereby alleviating financial burdens [13][14] - The overall goal of the procurement process is to maintain clinical stability while optimizing drug prices, which is crucial for patient care [14]